Clin2
NCT07314684Worth exploringRecruiting

Semaglutide's effect on inflammation in type 2 diabetes

T2DM (Type 2 Diabetes Mellitus)

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
80 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You have type 2 diabetes and are between 18 and 85 years old.
  • You have no known heart artery blockages of 50% or more (confirmed by a heart scan within the past 2 years).
  • Your heart pumping ability is at least 50% (normal or near normal).
  • You haven't taken semaglutide or similar GLP-1 medications before.
  • Your kidneys are working well (no moderate to severe kidney disease).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05819138Recruiting· Phase 3
Semaglutide for heart outcomes in adults with type 1 diabetes

This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.

Aurora, Colorado
NCT07272343Recruiting· Phase 4
Semaglutide vs. diet changes for new type 2 diabetes

This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.

Jiangxi, Nanchang
NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark
NCT07621419Recruiting
Semaglutide for Type 2 Diabetes in Real-World Care

This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.

Buenos Aires, Buenos Aires
NCT07165158Not yet recruiting· Phase 4
Semaglutide for bone health in type 2 diabetes

This study tests whether the diabetes medication semaglutide (which helps lower blood sugar) can also help protect your bones. It is for people with type 2 diabetes who have low bone density or a history of easy fractures, but not severe osteoporosis.

Xiamen, Fujian
NCT07046273Not yet recruiting· Phase 3
Semaglutide for type 2 diabetes: a phase 3 trial

This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.

Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.